Neil Kumar's most recent trade in BridgeBio Oncology Therapeutics Inc. was a trade of 31,675 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 16, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc | Neil Kumar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2026 | 31,675 | 31,675 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.74 per share. | 04 Jun 2026 | 15,921 | 4,338,897 (3%) | 0% | 67.7 | 1,078,452 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.74 per share. | 04 Jun 2026 | 15,921 | 536,136 (0%) | 0% | 67.7 | 1,078,454 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.88 per share. | 04 Jun 2026 | 8,437 | 4,322,862 (3%) | 0% | 67.9 | 572,744 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.88 per share. | 04 Jun 2026 | 8,437 | 520,102 (0%) | 0% | 67.9 | 572,744 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.20 per share. | 04 Jun 2026 | 7,148 | 4,331,299 (3%) | 0% | 67.2 | 480,338 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.20 per share. | 04 Jun 2026 | 7,147 | 528,539 (0%) | 0% | 67.2 | 480,271 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.96 per share. | 04 Jun 2026 | 4,416 | 515,686 (0%) | 0% | 69.0 | 304,524 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.96 per share. | 04 Jun 2026 | 4,415 | 4,318,447 (3%) | 0% | 69.0 | 304,455 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 65.72 per share. | 04 Jun 2026 | 2,200 | 553,486 (0%) | 0% | 65.7 | 144,584 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 65.72 per share. | 04 Jun 2026 | 2,200 | 4,356,247 (3%) | 0% | 65.7 | 144,584 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 66.72 per share. | 04 Jun 2026 | 1,429 | 4,354,818 (3%) | 0% | 66.7 | 95,347 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 66.72 per share. | 04 Jun 2026 | 1,429 | 552,057 (0%) | 0% | 66.7 | 95,347 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.27 per share. | 04 Jun 2026 | 450 | 4,338,447 (3%) | 0% | 68.3 | 30,721 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.27 per share. | 04 Jun 2026 | 450 | 535,686 (0%) | 0% | 68.3 | 30,721 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 70.48 per share. | 21 May 2026 | 11,250 | 244,127 (0%) | 0% | 70.5 | 792,916 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.30 per share. | 21 May 2026 | 6,725 | 260,449 (0%) | 0% | 68.3 | 459,334 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 69.22 per share. | 21 May 2026 | 5,072 | 255,377 (0%) | 0% | 69.2 | 351,102 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.57 per share. | 21 May 2026 | 2,256 | 267,174 (0%) | 0% | 67.6 | 152,435 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 70.92 per share. | 21 May 2026 | 800 | 243,327 (0%) | 0% | 70.9 | 56,735 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.13 per share. | 16 May 2026 | 36,236 | 269,430 (0%) | 0% | 66.1 | 2,396,287 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2026 | 33,544 | 267,995 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2026 | 33,544 | 100,632 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2026 | 19,599 | 287,594 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2026 | 19,599 | 137,195 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2026 | 11,553 | 299,147 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2026 | 11,553 | 127,092 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2026 | 6,519 | 305,666 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2026 | 6,519 | 97,794 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 66.65 per share. | 07 May 2026 | 13,974 | 4,364,473 (3%) | 0% | 66.7 | 931,374 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 66.65 per share. | 07 May 2026 | 13,973 | 561,713 (0%) | 0% | 66.7 | 931,307 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.49 per share. | 07 May 2026 | 11,217 | 584,469 (0%) | 0% | 67.5 | 757,091 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.49 per share. | 07 May 2026 | 11,217 | 4,387,230 (3%) | 0% | 67.5 | 757,090 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.38 per share. | 07 May 2026 | 8,334 | 4,378,896 (3%) | 0% | 68.4 | 569,858 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.38 per share. | 07 May 2026 | 8,333 | 576,136 (0%) | 0% | 68.4 | 569,790 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.35 per share. | 07 May 2026 | 5,077 | 556,636 (0%) | 0% | 67.3 | 341,913 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.35 per share. | 07 May 2026 | 5,076 | 4,359,397 (3%) | 0% | 67.3 | 341,846 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.35 per share. | 07 May 2026 | 950 | 4,358,447 (3%) | 0% | 68.3 | 64,930 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.35 per share. | 07 May 2026 | 950 | 555,686 (0%) | 0% | 68.3 | 64,930 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 69.09 per share. | 07 May 2026 | 450 | 575,686 (0%) | 0% | 69.1 | 31,091 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 69.09 per share. | 07 May 2026 | 449 | 4,378,447 (3%) | 0% | 69.1 | 31,022 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 74.60 per share. | 09 Apr 2026 | 20,000 | 595,686 (0%) | 0% | 74.6 | 1,492,096 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 74.60 per share. | 09 Apr 2026 | 20,000 | 4,398,447 (3%) | 0% | 74.6 | 1,492,076 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 75.53 per share. | 09 Apr 2026 | 7,800 | 4,418,447 (3%) | 0% | 75.5 | 589,124 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 75.55 per share. | 09 Apr 2026 | 7,500 | 615,686 (0%) | 0% | 75.6 | 566,661 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 73.64 per share. | 09 Apr 2026 | 7,200 | 628,486 (0%) | 0% | 73.6 | 530,240 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 73.64 per share. | 09 Apr 2026 | 7,072 | 4,431,375 (3%) | 0% | 73.6 | 520,801 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 74.60 per share. | 09 Apr 2026 | 5,300 | 623,186 (0%) | 0% | 74.6 | 395,403 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 74.57 per share. | 09 Apr 2026 | 5,128 | 4,426,247 (3%) | 0% | 74.6 | 382,379 | Common Stock |
| Maze Therapeutics Inc | Neil Kumar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2026 | 33,417 | 33,417 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2026 | 104,313 | 104,313 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2026 | 40,570 | 40,570 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.48 per share. | 12 Mar 2026 | 14,337 | 661,349 (0%) | 0% | 68.5 | 981,809 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.47 per share. | 12 Mar 2026 | 13,885 | 4,464,562 (3%) | 0% | 68.5 | 950,687 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 69.20 per share. | 12 Mar 2026 | 10,310 | 635,686 (0%) | 0% | 69.2 | 713,449 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.39 per share. | 12 Mar 2026 | 10,241 | 4,448,206 (3%) | 0% | 68.4 | 700,345 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 69.23 per share. | 12 Mar 2026 | 9,759 | 4,438,447 (3%) | 0% | 69.2 | 675,568 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.36 per share. | 12 Mar 2026 | 9,690 | 645,996 (0%) | 0% | 68.4 | 662,441 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 69.29 per share. | 12 Mar 2026 | 5,815 | 4,458,747 (3%) | 0% | 69.3 | 402,929 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 69.32 per share. | 12 Mar 2026 | 5,363 | 655,986 (0%) | 0% | 69.3 | 371,750 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 70.15 per share. | 12 Mar 2026 | 300 | 4,458,447 (3%) | 0% | 70.2 | 21,045 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 70.15 per share. | 12 Mar 2026 | 300 | 655,686 (0%) | 0% | 70.2 | 21,045 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 71.03 per share. | 19 Feb 2026 | 18,923 | 243,581 (0%) | 0% | 71.0 | 1,344,190 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 72.08 per share. | 19 Feb 2026 | 8,528 | 235,053 (0%) | 0% | 72.1 | 614,702 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 72.80 per share. | 19 Feb 2026 | 602 | 234,451 (0%) | 0% | 72.8 | 43,826 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2026 | 33,544 | 262,320 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2026 | 33,544 | 134,176 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.25 per share. | 16 Feb 2026 | 30,970 | 262,504 (0%) | 0% | 75.3 | 2,330,493 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2026 | 19,600 | 281,920 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2026 | 19,600 | 156,794 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2026 | 11,554 | 293,474 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2026 | 11,554 | 138,645 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 71.80 per share. | 10 Feb 2026 | 14,201 | 701,485 (0%) | 0% | 71.8 | 1,019,657 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 71.80 per share. | 10 Feb 2026 | 14,040 | 4,504,407 (3%) | 0% | 71.8 | 1,008,006 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 70.70 per share. | 10 Feb 2026 | 7,860 | 4,490,587 (3%) | 0% | 70.7 | 555,706 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 70.69 per share. | 10 Feb 2026 | 7,806 | 687,880 (0%) | 0% | 70.7 | 551,796 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 72.27 per share. | 10 Feb 2026 | 5,960 | 4,498,447 (3%) | 0% | 72.3 | 430,751 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 72.28 per share. | 10 Feb 2026 | 5,799 | 695,686 (0%) | 0% | 72.3 | 419,165 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 72.63 per share. | 10 Feb 2026 | 4,484 | 679,680 (0%) | 0% | 72.6 | 325,695 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 72.65 per share. | 10 Feb 2026 | 4,404 | 4,482,408 (3%) | 0% | 72.6 | 319,938 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 73.25 per share. | 10 Feb 2026 | 3,994 | 675,686 (0%) | 0% | 73.3 | 292,574 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 73.25 per share. | 10 Feb 2026 | 3,961 | 4,478,447 (3%) | 0% | 73.3 | 290,145 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 71.46 per share. | 10 Feb 2026 | 3,775 | 4,486,812 (3%) | 0% | 71.5 | 269,754 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 71.44 per share. | 10 Feb 2026 | 3,716 | 684,164 (0%) | 0% | 71.4 | 265,477 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 73.65 per share. | 08 Jan 2026 | 11,565 | 4,546,882 (3%) | 0% | 73.7 | 851,811 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 73.64 per share. | 08 Jan 2026 | 11,515 | 744,171 (0%) | 0% | 73.6 | 848,018 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 77.46 per share. | 08 Jan 2026 | 10,677 | 4,520,302 (3%) | 0% | 77.5 | 827,016 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 77.61 per share. | 08 Jan 2026 | 10,519 | 716,061 (0%) | 0% | 77.6 | 816,365 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 74.38 per share. | 08 Jan 2026 | 8,135 | 4,538,747 (3%) | 0% | 74.4 | 605,061 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 74.38 per share. | 08 Jan 2026 | 8,085 | 736,086 (0%) | 0% | 74.4 | 601,340 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 76.72 per share. | 08 Jan 2026 | 6,955 | 726,580 (0%) | 0% | 76.7 | 533,569 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 76.53 per share. | 08 Jan 2026 | 6,067 | 4,530,979 (3%) | 0% | 76.5 | 464,289 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 75.75 per share. | 08 Jan 2026 | 2,151 | 733,535 (0%) | 0% | 75.8 | 162,943 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 78.10 per share. | 08 Jan 2026 | 1,855 | 4,518,447 (3%) | 0% | 78.1 | 144,882 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 75.61 per share. | 08 Jan 2026 | 1,401 | 4,537,046 (3%) | 0% | 75.6 | 105,928 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 75.16 per share. | 08 Jan 2026 | 400 | 735,686 (0%) | 0% | 75.2 | 30,064 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 78.19 per share. | 08 Jan 2026 | 375 | 715,686 (0%) | 0% | 78.2 | 29,322 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 75.20 per share. | 08 Jan 2026 | 300 | 4,538,447 (3%) | 0% | 75.2 | 22,561 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 60,975 | 289,751 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 60,975 | 60,976 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.15 per share. | 12 Dec 2025 | 30,964 | 258,787 (0%) | 0% | 75.2 | 2,326,945 | Common Stock |